Biological Therapeutics Lab
The Biological Therapeutics Lab is focused on the development and characterization of novel biological therapeutic agents, in the form of monoclonal antibodies (mAbs) and short-interfering RNA (siRNA), to various diseases including cancer. In conjunction with the Cancer Drug Development Lab within the Pharmaceutical Genomics Division, we will further investigate gene targets identified from the high throughput RNA interference (HT-RNAi) screens using immunochemical and molecular biological techniques. This research will be part of the collaborative translational research at TGen that will focus on targeting functionally identified disease genes with protein and nucleic acid-based therapeutics.
Current Projects:
1. Identification of cancer associated genes in pancreatic cancer using HT-RNAi.
2. Development of functional antibodies targeting pancreatic cancer associated genes.
3. Targeting membrane associated proteins to improve chemotherapy in breast cancer.
4. Functional analysis of genes associated in prostate cancer.
Staff:
David Azorsa, Ph.D., Unit Head
Gargi Basu, Ph.D., Staff Scientist
Irma Monzon, Research Associate
Joseph Hernandez, Research Associate
|
E-MAIL THIS ARTICLE
PRINT THIS PAGE
Podcasts
NewsFeed